title: Breast cancer and obesity: in vitro interferences between adipokines and proangiogenic features and/or antitumor therapies?
abstract: Obesity is now considered as a risk factor for breast cancer in postmenopausal women. Adipokine levels are modulated in obesity, and may play a role in carcinogenesis. Moreover, obesity increases risk of cancer mortality. Here, we hypothesized that this increase could be due to a modification in angiogenesis, capital event in the development of metastases, and/or in effectiveness of cancer treatments. To test these assumptions, following a same experimental design and simultaneously the effects of leptin and adiponectin on angiogenesis were investigated, and the impact of hyperleptinemia on anticancer drug effectiveness was measured in physiological and obesity situations. Focusing on angiogenesis, the proliferation of endothelial cells (HUVEC), which expressed leptin and adiponectin receptors, was stimulated by leptin and inhibited by adiponectin. Both adipokines globally reduced apoptosis and caspase activity. Leptin increased migration whereas adiponectin decreased migration, and leptin enhanced the area of the tubes formed by HUVEC cells while adiponectin inhibited their formation. MCF7 and MDA-MB-231 cells treated with leptin secreted more VEGF than untreated cells, whereas adiponectin treatment inhibited VEGF secretion. Finally, MCF7 cells pre-treated with leptin were more invasive than untreated cells. This effect was not reproduced in MDA-MB-231 cells. In the MCF7 breast cancer cell line, leptin could induce cell proliferation and reduced the efficacy of all breast cancer therapies (tamoxifen, 5-fluorouracil, taxol and vinblastin). These results suggest that, in obesity situation, leptin- in contrast to adiponectin - may promote tumor invasion and angiogenesis, leading to metastases 'apparition, and reduce treatment efficacy, which could explain the increased risk of cancer mortality in cases of overweight. The evidence suggests adipokines influence breast cancer issue and could play a significant role, especially in obese patients for which hyperleptinemia, hypoadiponectinemia and increased metastatic potential are described.
authors.affiliation: Clermont Université, Université d'Auvergne, UFR Pharmacie, Laboratoire SVFp, Clermont-Ferrand, France.
authors.forename: Virginie
authors.initials: V
authors.lastname: Dubois
authors.forename: Laetitia
authors.initials: L
authors.lastname: Delort
authors.forename: Hermine
authors.initials: H
authors.lastname: Billard
authors.forename: Marie-Paule
authors.initials: MP
authors.lastname: Vasson
authors.forename: Florence
authors.initials: F
authors.lastname: Caldefie-Chezet
mesh_terms: D052242:Adiponectin / Q000378:metabolism* / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000187:drug effects; D005260:Female; D061307:Human Umbilical Vein Endothelial Cells; D006801:Humans; D020738:Leptin / Q000378:metabolism* / Q000494:pharmacology; D009361:Neoplasm Invasiveness; D009363:Neoplasm Proteins / Q000378:metabolism*; D009389:Neovascularization, Pathologic / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D009765:Obesity / Q000378:metabolism* / Q000473:pathology; D054411:Receptors, Leptin / Q000378:metabolism; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism*
chemical_list: C499918:ADIPOQ protein, human; D052242:Adiponectin; D000970:Antineoplastic Agents; C515448:LEPR protein, human; D020738:Leptin; D009363:Neoplasm Proteins; D054411:Receptors, Leptin; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A
references.citation: Blood. 1997 Nov 1;90(9):3438-43
references.pmid: 9345027
references.citation: Biochem Biophys Res Commun. 2008 Mar 28;368(1):1-5
references.pmid: 18242580
references.citation: Proc Soc Exp Biol Med. 1997 Oct;216(1):28-43
references.pmid: 9316608
references.citation: Endocr Relat Cancer. 2010 Apr 21;17(2):373-82
references.pmid: 20410173
references.citation: Diabetes Metab. 2004 Feb;30(1):13-9
references.pmid: 15029093
references.citation: Basic Res Cardiol. 1991;86 Suppl 2:7-16
references.pmid: 1719954
references.citation: Eur J Endocrinol. 2002 Aug;147(2):173-80
references.pmid: 12153737
references.citation: Cancer Res. 2006 Dec 1;66(23):11462-70
references.pmid: 17145894
references.citation: Jpn J Clin Oncol. 2001 Sep;31(9):424-7
references.pmid: 11689595
references.citation: J Biol Chem. 2004 Jan 9;279(2):1304-9
references.pmid: 14557259
references.citation: Transl Oncogenomics. 2008 Mar 17;3:45-52
references.pmid: 21566743
references.citation: Int J Cancer. 2006 Jan 15;118(2):458-66
references.pmid: 16049963
references.citation: Oncogene. 2003 Sep 25;22(41):6408-23
references.pmid: 14508521
references.citation: Clin Cancer Res. 2004 Jul 1;10(13):4325-31
references.pmid: 15240518
references.citation: Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14564-8
references.pmid: 8962092
references.citation: Int J Obes. 1991 Sep;15 Suppl 2:67-81
references.pmid: 1794941
references.citation: Clin Cancer Res. 2004 Aug 15;10(16):5375-80
references.pmid: 15328175
references.citation: Breast Cancer Res Treat. 2006 Jul;98(2):121-32
references.pmid: 16752079
references.citation: Proc Natl Acad Sci U S A. 2001 May 22;98(11):6390-5
references.pmid: 11344271
references.citation: Endocr Relat Cancer. 2007 Jun;14(2):189-206
references.pmid: 17639037
references.citation: Endocr Relat Cancer. 2009 Dec;16(4):1197-210
references.pmid: 19661131
references.citation: Exp Mol Med. 2001 Jun 30;33(2):95-102
references.pmid: 11460888
references.citation: Nat Rev Cancer. 2004 Aug;4(8):579-91
references.pmid: 15286738
references.citation: Trends Endocrinol Metab. 2000 Oct;11(8):327-32
references.pmid: 10996528
references.citation: Nature. 1997 May 8;387(6629):206-9
references.pmid: 9144295
references.citation: Cancer Metastasis Rev. 2010 Dec;29(4):641-53
references.pmid: 20821253
references.citation: Physiol Res. 2006;55(3):233-44
references.pmid: 16238454
references.citation: Cancer Epidemiol Biomarkers Prev. 2005 Jul;14(7):1686-91
references.pmid: 16030102
references.citation: Science. 1998 Sep 11;281(5383):1683-6
references.pmid: 9733517
references.citation: J Korean Med Sci. 2007 Feb;22(1):117-21
references.pmid: 17297263
references.citation: Circ Res. 1998 Nov 16;83(10):1059-66
references.pmid: 9815153
references.citation: Endocrine. 2005 Feb;26(1):19-24
references.pmid: 15805581
references.citation: Clin Cancer Res. 2006 Mar 1;12(5):1447-53
references.pmid: 16533767
references.citation: Endokrynol Pol. 2007 Jan-Feb;58(1):2-6
references.pmid: 17354198
references.citation: Nutr Cancer. 2003;45(1):1-16
references.pmid: 12791499
references.citation: Science. 1995 Jul 28;269(5223):540-3
references.pmid: 7624776
references.citation: Endocr Relat Cancer. 2006 Jun;13(2):279-92
references.pmid: 16728564
references.citation: Circ Res. 2004 Mar 5;94(4):e27-31
references.pmid: 14752031
references.citation: Br J Cancer. 2006 May 8;94(9):1221-5
references.pmid: 16570048
references.citation: Nat Med. 2001 Aug;7(8):941-6
references.pmid: 11479627
references.citation: Breast Cancer Res Treat. 2010 Jan;119(2):367-7
references.pmid: 19842034
references.citation: Hypertension. 2002 Nov;40(5):748-54
references.pmid: 12411472
references.citation: Maturitas. 2000 May 29;35(2):175-9
references.pmid: 10924844
references.citation: J Biol Chem. 1997 May 16;272(20):12897-900
references.pmid: 9148892
references.citation: Mol Cell Endocrinol. 2010 Mar 25;316(2):129-39
references.pmid: 19723556
references.citation: Biochem Biophys Res Commun. 2006 Jun 23;345(1):271-9
references.pmid: 16678125
references.citation: Clin Cancer Res. 2009 May 15;15(10):3265-76
references.pmid: 19447867
references.citation: Proc Natl Acad Sci U S A. 2004 Feb 24;101(8):2476-81
references.pmid: 14983034